SOLICITATION NOTICE
66 -- 2016 NCI Surgery Branch Genetic Analysis Sequencer
- Notice Date
- 8/18/2016
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- RFQ_8121618
- Archive Date
- 9/13/2016
- Point of Contact
- Carrie L. Mills, Phone: 3016241274
- E-Mail Address
-
carrie.mills@nih.gov
(carrie.mills@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Surgery Branch (SB), plans to procure on a sole source basis a Next SeqTM 550 high-throughput desktop DNA sequencer equipment, including one-year service agreement, from Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122. The acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(2) and 41 U.S.C. 1901 and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 334516 "Analytical Laboratory Instrument Manufacturing" and the business size standard is 1,000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The National Cancer Institute (NCI), Surgery Branch (SB), is a part of the National Institutes of Health. NCI SB has a requirement to procure a high-throughput desktop sequencer to facilitate the efforts to develop novel immunotherapies for the treatment of patients with a variety of malignancies that include melanoma, gastrointestinal, lung, and bladder cancer. This equipment will be used to acquire whole genome, whole exome and whole transcriptome data that is essential for carrying out ongoing high priority projects to identify mutated antigens recognized by patient tumor-reactive T cells. Identification of these targets provides us with powerful tools to guide cancer immunotherapy. The utilization of NGS genomic and proteomic studies will have significant applications for the treatment of a large population of patients with a variety of malignancies. The NCI has extensive experience conducting high-throughput sequencing experiments using Illumina platforms. The laboratory has completed over ~100 whole exomes and ~85 transcriptomes generated from Ilumina platforms. To facilitate and accelerate this type of research in the future, the NCI requires an Illumina NextSeq 550 sequencer to increase capacity to process samples for NCI SB. To ensure the continuity of ongoing experiments, NCI must continue to use an Illumina platform for three related reasons. First, NCI must be sure that the sequencing results in the future can be analyzed in combination with the sequencing data already in hand. Other sequencing technologies use different molecular mechanisms for sequencing and different analytics that leads to platform-specific sequencing artifacts. Therefore, in order to insure comparability of new sequencing data with our extensive database of sequencing in malignancies, NCI has to continue to use an Illumina platform. Otherwise, NCI would risk contaminating analyses by platform-specific sequencing artifacts. Second, it is important that the libraries that are constructed for sequencing on a NextSeq 500 platform can be used directly on any of the Illumina sequencers; MiSeq, NextSeq 550 and the HiSeq 3000/4000 series. Finally, all of the proprietary analytic pipelines that NCI has developed for RNA-seq, exome-seq, and whole genome-seq are geared towards Illumina reagents and kits and would have to be completely recoded to use data from another type of sequencing machine. The Contractor shall provide/perform the following, unless otherwise noted: TECHNICAL REQUIREMENTS: The Contractor shall deliver one (1) Illumina NextSeqTM 550 high-throughput desktop DNA sequencer, including a one-year service agreement. Under the service agreement the contractor shall respond with 24 hrs. and be onsite within an additional 24 hrs. to provide service. Salient Characteristics: • Scalability from 40-150 Gb in a single run to support a broad range of applications and study sizes • The ability to perform runs, including onboard cluster generation, in 24-30 hours • Must have fully automated onboard cluster generation to enable prepped libraries to be loaded directly onto the instrument • Must have SBS chemistry with single-base extension enables accurate sequencing of homopolymers • Must have the capability of scanning microarray chips within the same compartment as the flow cell • Must have fully automated paired-end sequencing • Equipment must be a single unit that is able to fit in ~2 ft. by 2 ft. space. Illumina Inc. is the only known manufacturer of a NextSeqTM 550 Sequencing System with the above salient characteristics that also uses the same platform, chemistry and library generation features to maintain scientific comparability with existing methods. REPORTING REQUIREMENTS AND DELIVERABLES: The Contractor shall deliver the instrument within 30 days after the purchase order is awarded to: NCI Surgery Branch in Bethesda, MD. The Contractor that receives the award will be provided with the complete mailing address and point of contact. Inspection/Acceptance will be at destination. PAYMENT: Net 30 days from date of invoice. Payment shall be made after acceptance of the deliverables, and submission of invoice pursuant to the invoicing instructions, and to the address shown, in the contract/order. AWARD: Award will be made in the aggregate. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 2:00PM EDT, on Monday August 29, 2016. All responses and questions must be in writing and sent to Carrie Mills, Contracting Specialist, via electronic mail at carrie.mills@nih.gov. A determination by the Government not to complete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have a valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference RFQ# 8121618 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/RFQ_8121618/listing.html)
- Place of Performance
- Address: NCI Surgery Branch, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04231458-W 20160820/160819000942-15f6acdb6b9a18765688aa4b27091aee (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |